Dr Reddy’s Laboratories has expanded its collaboration with Sanofi Healthcare to bring Beyfortus, a novel preventive therapy against respiratory syncytial virus (RSV) disease, to India. The Hyderabad-based pharma major will exclusively promote and distribute the drug in the Indian market.

Key Highlights

Exclusive Distribution Partnership

• Dr Reddy’s will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.

• This builds upon their earlier partnership covering Sanofi’s vaccine portfolio in India.

About Beyfortus

• Beyfortus contains the monoclonal antibody nirsevimab and is administered via a prefilled injection.

• It is approved for prevention of LRTD caused by RSV in infants and newborns, and in children less than 24 months of age who are at risk of severe RSV.

Planned Launch Timeline
Beyfortus will be launched by Dr Reddy's in India in the second quarter of the ongoing fiscal year.

Global and Indian Approvals

• Beyfortus has obtained regulatory clearances in the European Union, the US, China, Japan, and many other nations.

• In India, it got approval for marketing authorization from CDSCO in June 2024.

Quotes of Officials or Leaders
MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories:
"Beyfortus allows parents and healthcare professionals to have access to a better drug in RSV prevention."Nitya Padmanabhan, Head of Sanofi Vaccines (India):
"Taking Beyfortus to India is a landmark move towards our vision of safeguarding all children against immunisation avoidable diseases such as RSV."The launch of Beyfortus represents a milestone development in the pediatric healthcare landscape in India, with a revolutionary solution to safeguard young children and infants from severe cases of RSV infection. The collaboration reiterates Dr Reddy's strategic focus on enhancing access to advanced global therapies.